Helix.

A blood draw in Reno is rewriting how medicine gets practiced.

Somewhere in Nevada, a patient hands over a tube of saliva during an ordinary checkup. No drama. No specialist referral. That sample travels to a lab in San Mateo, gets read across roughly 20,000 genes, and comes back as something most healthcare has never had: a permanent, queryable record of what that person's biology is likely to do next. Years later, when a new drug or a new screening guideline appears, the same sample answers again - no second needle required.

This is Helix's whole argument, compressed into one vial. The company doesn't sell a single test. It sells the idea that DNA belongs in the chart, sitting next to blood pressure and cholesterol, doing useful work for decades. Health systems run the programs. Helix runs the genomics underneath them.

Genomics had a discovery problem solved, and a plumbing problem ignored.

By the mid-2010s, sequencing a genome was no longer the hard part. Costs were collapsing. Research papers were piling up. The trouble was that almost none of it reached the people sitting in exam rooms. A consumer might spit in a tube and get back ancestry charts and a few novelty traits. A researcher might assemble a cohort and publish. But the clinic - where genetics could actually change a prescription or catch a cancer early - stayed mostly untouched.

The reasons were boring, which is exactly why they were stubborn. Most tests sequenced one thing, answered one question, and then the data was effectively thrown away. Re-asking meant re-sequencing. Health systems had no clean way to fold genomic results into the workflows clinicians already used. Genomics, for all its glamour, didn't have any plumbing.

Translation: the breakthrough wasn't a better microscope. It was a better filing system for biology.

Three founders, one heretical idea: sequence once, ask forever.

Helix was founded in 2015 by James Lu, Justin Kao, and Scott Burke, spun out with backing from sequencing giant Illumina. Lu, who became CEO, had wandered the intersection of clinical care and genomics since the early days of next-generation sequencing. He had been a faculty member at Duke - in both engineering and medicine, which tells you something - and left after a year to chase this instead.

The founding bet was almost suspiciously simple. Instead of selling people a one-shot test, sequence a person's exome once, store it well, and let new insights be unlocked from the same sample over time. It is the difference between buying a single song and owning the record. The model only works if the underlying sequencing is broad and accurate enough to be trusted for years - which is why Helix didn't just settle for a standard panel.

James Lu gave up tenure-track stability for a saliva tube. The early-2010s version of running away to join the circus.

Exome+ , and the assay that talked its way past the FDA.

At the center sits the Exome+ assay: a sequencing approach that reads the roughly 20,000 genes that code for proteins, plus around 300,000 informative non-coding regions that a standard exome test would skip. More signal in the same sample means more questions can be answered later - the technical backbone of "sequence once, ask forever."

Then came the part that's genuinely hard to copy. In January 2021, the Helix Laboratory Platform became the first - and for a while the only - whole exome sequencing platform to receive FDA de novo authorization. Helix essentially worked with regulators to invent a new category for a broad sequencing-based device. In a field where "first FDA-authorized" usually applies to a narrow assay, getting an entire exome platform cleared was a different order of difficulty.

The receipts: who's buying, and how big the cohorts got.

A clever model is worth nothing if no serious institution trusts it. Helix's answer is its partner list. Mayo Clinic - also an investor - launched the Tapestry study and committed to building a genomic library of 100,000 participants. Renown Health in Nevada grew the Healthy Nevada Project's ambitions from 40,000 toward 250,000 residents, and the two published one of the largest genome-wide rare variant analyses to date, drawing on over 70,000 exomes.

The roster kept widening: Ohio State University Wexner Medical Center launched what it billed as the largest precision health initiative in Ohio, and St. Luke's University Health Network opened its own population genomics program. On the life sciences side, Helix partnered with Recursion to pair clinico-genomic data with AI for drug discovery.

Each bar is a stack of consent forms taller than the lab building. Genomics, it turns out, is mostly paperwork and patience.

Make the genome boring - on purpose.

Helix's stated mission is to empower every person to improve their life through DNA. In practice that means a stranger goal than it first sounds: making genomics so ordinary that nobody talks about it. Not a special event. Not a frightening referral. Just another line in the record that helps a doctor catch a hereditary cancer risk early, or avoid prescribing a drug a patient can't safely metabolize.

There's a public health dimension too. The same infrastructure that reads an individual's exome can, at scale, surveil a virus - which is why a precision medicine company spent the pandemic quietly running one of the country's larger SARS-CoV-2 surveillance operations. The plumbing, once built, carries more than one kind of water.

What you can actually do with it

Through a partnered health system, a patient can get proactive screening for hereditary cancer and heart conditions, pharmacogenomic guidance that makes prescriptions safer, and the option to have results updated as science advances - all from one sample. Health systems get a turnkey way to run population health programs; researchers and biopharma get consented, real-world clinico-genomic data.

Back to that tube in Nevada.

Return to the patient who handed over a sample during a routine checkup. A decade ago, that tube would have answered one question and been discarded. Today, it sits in a record that a clinician can re-query as guidelines change, that a researcher can study with consent, and that a public health agency can lean on in a crisis. The patient did nothing different. The system around the patient changed.

That's the quiet shift Helix is chasing - not a flashy gadget, but a different default for what medicine knows about you before you walk in. Whether genomics truly becomes as routine as a blood pressure cuff is still an open question, and skeptics are right to ask whether the economics and the evidence will fully arrive. But the infrastructure for that future now exists, it's FDA-authorized, and it's already running inside some of the most cautious hospitals in the country.

One sample. Asked once. Useful for a lifetime. That was the bet in 2015. The receipts are starting to come in.

Watch & listen